| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/09/2011 | US7994282 Card proteins involved in cell death regulation |
| 08/09/2011 | US7994219 Approach to anti-microbial host defense with molecular shields with lipoxin compounds |
| 08/09/2011 | US7994217 Prenatal multivitamin/multimineral supplement |
| 08/09/2011 | US7994212 For therapy of of neoplastic diseases |
| 08/09/2011 | US7994193 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| 08/09/2011 | US7994137 Using f-met-leu-x peptides to modify lymphocyte response to immunoglobulin-e challenge; inhibiting t-cell migration; immunotherapy |
| 08/09/2011 | US7994114 Chemokine mimetics synthesis and their use |
| 08/09/2011 | US7993834 Detection of ErbB2 gene amplification to increase the likelihood of the effectiveness of ErbB2 antibody breast cancer therapy |
| 08/09/2011 | US7993829 HPRP4s modifiers of the p53 pathway and methods of use |
| 08/09/2011 | US7993673 Fast acting paracetamol formulation containing a small amount of antacid |
| 08/09/2011 | US7993669 synergistic efficacy; polar lipid supplement, a soluble fiber, and a nutricine such as threonine |
| 08/09/2011 | US7993660 Method of increasing immunological effect |
| 08/09/2011 | US7993659 TLR9 agonist and CD40 agonist immunostimulatory combinations |
| 08/09/2011 | US7993639 Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases |
| 08/09/2011 | CA2529507C Compounds and methods for inducing apoptosis in cancer cells |
| 08/09/2011 | CA2487297C The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases |
| 08/09/2011 | CA2474645C Compositions and methods for systemic inhibition of cartilage degradation |
| 08/09/2011 | CA2465813C Processed baby food with unsaturated fatty acids and/or nucleotides |
| 08/09/2011 | CA2463938C Polymer conjugates of opioid antagonists |
| 08/09/2011 | CA2450179C Identification of stat6 modulators using ncoa-1/stat6 interaction |
| 08/09/2011 | CA2447921C Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 08/09/2011 | CA2445190C Indole, azaindole and related heterocyclic amidopiperazine derivatives |
| 08/09/2011 | CA2438092C Ttk in diagnosis and as a therapeutic target in cancer |
| 08/09/2011 | CA2432568C Benzoylpyridazines |
| 08/09/2011 | CA2380058C Novel peptides |
| 08/09/2011 | CA2367360C Insulin-like growth factor binding protein-4 protease |
| 08/09/2011 | CA2293415C Compositions for treating and preventing arterial thrombosis and use of a factor xa inhibitor on its own and/or combined with a platelet antiaggregating agent |
| 08/09/2011 | CA2291721C Ribosome complexes as selection particles for in vitro display and evolution of proteins |
| 08/04/2011 | WO2011094285A1 Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization |
| 08/04/2011 | WO2011093829A1 Effervescent formulations comprising cefixime and clavulanic acid as active agents |
| 08/04/2011 | WO2011093827A1 Water dispersible cefdinir and clavulanic acid formulations for treatment of bacterial infections |
| 08/04/2011 | WO2011093822A1 Effervescent formulations comprising cefixime and clavulanic acid as active agents |
| 08/04/2011 | WO2011093821A1 Effervescent formulations comprising cefdinir and clavulanic acid |
| 08/04/2011 | WO2011093819A2 New combination comprising tiotropium |
| 08/04/2011 | WO2011093818A2 Pharmaceutical compositions comprising salmeterol and fluticasone |
| 08/04/2011 | WO2011093817A1 Pharmaceutical compositions comprising tiotropium, formoterol and budesonide |
| 08/04/2011 | WO2011093811A2 Pharmaceutical preparations comprising formoterol and fluticasone |
| 08/04/2011 | WO2011093808A1 Tissue renewing mixture for burn wound cure |
| 08/04/2011 | WO2011049948A4 Neuroprotection and myelin repair using nestorone® |
| 08/04/2011 | US20110191873 Methods of Protein Destabilization and Uses Thereof |
| 08/04/2011 | US20110190308 Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| 08/04/2011 | US20110190277 Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases |
| 08/04/2011 | US20110190144 Novel compositions and methods for the treatment of psoriasis |
| 08/04/2011 | US20110189789 Novel target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto |
| 08/04/2011 | US20110189139 Hematopoietic Cell E-Selectin/L-Selectin Ligand Glycosylated CD44 Polypeptide |
| 08/04/2011 | US20110189103 Aerosolized Fosfomycin/Aminoglycoside Combination for the Treatment of Bacterial Respiratory Infections |
| 08/03/2011 | EP2351852A1 RNA interference mediating small RNA molecules |
| 08/03/2011 | EP2351840A1 Polypeptides involved in immune response |
| 08/03/2011 | EP2351832A1 Composition for inducing th2 cell, therapeutic composition for th2-type disease, and use of same |
| 08/03/2011 | EP2351570A1 An Antibiotic/Analgesic Formulation And a Method of Making This Formulation |
| 08/03/2011 | EP2351567A2 Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-iv, and other antidiabetic or antiobesity agents as active ingredients |
| 08/03/2011 | EP2351563A1 Agent for treatment of diabetes |
| 08/03/2011 | EP2351561A2 Novel methods and compositions for alleviating pain |
| 08/03/2011 | EP2350642A1 Na/k-atpase expression as an indicator for the treatment of cancer |
| 08/03/2011 | EP2350641A1 Method of treatment |
| 08/03/2011 | EP2350305A1 Combination treatments comprising protease binding proteins for inflammatory disorders |
| 08/03/2011 | EP2350096A1 Methods of treating hepatic encephalopathy |
| 08/03/2011 | EP2349335A1 Levetiracetam immunoassays |
| 08/03/2011 | EP2349334A1 S1p receptor agonists for the treatement of cerebral malaria |
| 08/03/2011 | EP2349328A1 Methods for the treatment of cancer |
| 08/03/2011 | EP2349313A1 Combination therapy with peptide epoxyketones |
| 08/03/2011 | EP2349311A1 Compositions and methods for treatment of radiation exposure |
| 08/03/2011 | EP2349290A1 Use of helium-oxygen gas mixtures for treating pulmonary arterial hypertension |
| 08/03/2011 | EP2349252A2 Synergistic combination of sphingosine-1-phosphate receptor antagonists and antimicrotubule agents |
| 08/03/2011 | EP2349248A2 Topical nsaid compositions having sensate component |
| 08/03/2011 | EP2349245A2 Treatment of retroviral reservoirs exploiting oxidative stress |
| 08/03/2011 | EP2004168B1 Stable oral pharmaceutical composition containing thyroid hormone receptor agonists |
| 08/03/2011 | EP1843754B1 New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance |
| 08/03/2011 | EP1480634B1 Selective androgen receptor modulators (SARMs) for treating benign prostate hyperplasia |
| 08/03/2011 | EP1446104B2 Spray drying methods |
| 08/03/2011 | EP1391202B1 Liquid drug preparations |
| 08/03/2011 | EP1212055B1 Neurotherapeutic composition comprising a beta-lactam compound |
| 08/03/2011 | CN102143761A Agent for treating myelofibrosis |
| 08/03/2011 | CN102143748A Combination therapy for tuberculosis |
| 08/03/2011 | CN102143742A Phosphate binding materials and their uses |
| 08/03/2011 | CN102139110A Use of angiotensin II receptor antagonists, especially telmisartan, in order to increase insulin sensitivity |
| 08/03/2011 | CN102139109A Quality-stable preparation composition of angiotensin converting enzyme inhibitor |
| 08/03/2011 | CN102139108A Co-ground materials of benzimidazoles proton pump inhibitors and hydrophilic polymer auxiliary materials |
| 08/03/2011 | CN102139107A Anticancer effect of antagonist of neurokinin receptor |
| 08/03/2011 | CN102138932A Buffered compositions for dialysis |
| 08/03/2011 | CN101316590B Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| 08/02/2011 | US7989491 Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections |
| 08/02/2011 | US7989489 Synergistic mixtures |
| 08/02/2011 | US7989474 Use of Lck inhibitors for treatment of immunologic diseases |
| 08/02/2011 | US7989210 IL1RL-1 as a cardiovascular disease marker and therapeutic target |
| 08/02/2011 | US7989182 Nucleic acid encoding SCN1A variant |
| 08/02/2011 | US7988997 Matrix of water soluble polymer; solidificated foam |
| 08/02/2011 | US7988989 Nutritional product for enhancing growth and/or strengthening the immune system of equine foals |
| 08/02/2011 | US7988965 Methods of treating systemic lupus erythematosus with an antibody against costimulatory signal transduction molecule ailim |
| 08/02/2011 | US7988952 Condensation aerosol formed by heating a thin layer containing the ester, on a solid support to produce a vapor of the ester, and condensing; less than 10% ester degradation products by weight, and a Mass median aerodynamic diameter of less than 5 microns |
| 08/02/2011 | CA2668311C Enhancing photodamage caused by ultraviolet light using a 3-hydroxypyridine analog |
| 08/02/2011 | CA2523859C Methods and devices for the sustained release of multiple drugs |
| 08/02/2011 | CA2498735C Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines |
| 08/02/2011 | CA2478278C Micronutrient supplement |
| 08/02/2011 | CA2470956C 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives and their use as muscarinic receptor antagonists |
| 08/02/2011 | CA2449059C Polymer controlled induced viscosity fiber system and uses thereof |
| 08/02/2011 | CA2447010C Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 08/02/2011 | CA2423999C Compositions and medical devices utilizing bioabsorbable liquid polymers |
| 08/02/2011 | CA2417984C Methods for treating autoimmune and chronic inflammatory conditions using antagonists of cd30 or cd30l |
| 08/02/2011 | CA2391685C Medicinal implant and device and method for loading and delivering implants containing drugs and cells |